021-5137-0935
sales@aqbiopharma.com.cn
Yangzhou Fluoropharma Technology Co., Ltd. was founded in 2011 by a team including winners of the Second Prize of the National Natural Science Award, Jiangsu Provincial Double Innovation Talents and multiple overseas-returned PhDs. It is a professional fluorinated pharmaceutical technology enterprise in China.
The company focuses on the R&D of fluorinated pharmaceutical products and corresponding process technologies, covering new fluorinated drugs and their intermediates. Our products and technologies cover all stages of the pharmaceutical value chain: preclinical new drug research, Phase I, II and III clinical trials, and commercialized marketed products. We specialize in the R&D, production, sales and technology licensing of new fluorinated drug scaffolds featuring rare heterocyclic structures.
Our core mature R&D products feature proprietary technical advantages. For the R&D and manufacturing of fluorinated pharmaceuticals, we adopt self-developed fluorinated building block technology to replace traditional fluorination techniques, enabling industrialized production and strengthening our market competitiveness. We currently hold a number of core patented technologies.
Our short and medium-term goal is to continuously develop internationally competitive fluorinated pharmaceutical products and technologies to expand market share. Our long-term goal lies in the research and development of fluorine-based generic drugs and novel fluorinated drugs.[View details]
Congratulations on the successful project of "Shanghai Green Fluoropharmaceutical Engineering Technology Research Center" jointly established by Aqikang Medical Science and Technology and Shanghai University of Applied Technology!
Nucleic acid drugs are drugs that use the translation or regulation function of nucleic acid molecules to intervene in diseases. Compared with traditional small molecule drugs and antibody drugs, nucleic acid drugs can intervene at the source, inhibit the expression of disease-related genes into pathological proteins, or introduce genes that can express normal proteins.
No content！
